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Abstract
Background: Chronic diseases impose large economic burdens. Cost analysis is not straightforward, particularly
when the goal is to relate costs to specific patterns of covariates, and to compare costs between diseased and
healthy populations. Using different statistical methods this study describes the impact on results and conclusions
of analyzing health care costs in a population with diabetes.
Methods: Direct health care costs of people living in Turin were estimated from administrative databases of the
Regional Health System. Patients with diabetes were identified through the Piedmont Diabetes Registry. The effect
of diabetes on mean annual expenditure was analyzed using the following multivariable models: 1) an ordinary
least squares regression (OLS); 2) a lognormal linear regression model; 3) a generalized linear model (GLM) with
gamma distribution. Presence of zero cost observation was handled by means of a two part model.
Results: The OLS provides the effect of covariates in terms of absolute additive costs due to the presence of diabetes
(€ 1,832). Lognormal and GLM provide relative estimates of the effect: the cost for diabetes would be six fold that for
non diabetes patients calculated with the lognormal. The same data give a 2.6-fold increase if calculated with the GLM.
Different methods provide quite different estimated costs for patients with and without diabetes, and different costs
ratios between them, ranging from 3.2 to 5.6.
Conclusions: Costs estimates of a chronic disease vary considerably depending on the statistical method employed;
therefore a careful choice of methods to analyze data is required before inferring results.
Keywords: Lifetime costs, Chronic diseases, Diabetes Mellitus, Modeling techniques
Background
Chronic diseases impose a large economic burden on
the individual, national healthcare systems, and coun-
tries [1]. Awareness of such economic burden has led to
a sharp increase in the number of studies on economic
issues related to chronic diseases [2]. However, it should
be emphasized that the estimation of mean patient cost
is not straightforward, particularly when the goal of the
analysis is to relate costs to a specific pattern of covari-
ates, and to compare costs between people with and
without the disease [3].
The following criticisms often characterize the medical
cost data distribution:
– Skewness, due to the presence of a minority of
subjects with higher medical cost compared with
the rest of the population. This cannot be bypassed
excluding the outliers from the analyses, as errors or
looking to more robust measures such as the
median value. Indeed, all observations are of interest
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in the decision-making process, providing additional in-
formation on health care service utilization and related
costs of subgroups of the examined population [4];
– Presence of zero-cost observations due to the lack of
treatment in some subgroups of the analysed popu-
lation. Indeed, people with positive and those with
zero-costs are likely to have different behaviour pat-
terns in relation to the covariates, such as age co-
morbidities, socioeconomic level and access to
health care services [5, 6];
– Presence of censored data, which do not allow to
observe the subjects’ costs over the entire period of
interest, mainly life-time span or the study follow
up. Such censoring does not usually satisfy the con-
dition of being independent and not informative, so
that individuals who remain under observation are
generally not representative of the population at risk
in each group [7, 8]; and
– Clustering of data, that is the presence of correlation
between costs and outcomes. Indeed, clinical
practice differs according to the centre or the
general practitioner and patient case-mix [9–11].
Both the afore mentioned issues and methodological
approaches for their handling have been widely debated
in literature. Several appropriate statistical methods are
now agreed upon and recommended [3, 12, 13]. In spite
of a large amount of papers on costs of chronic diseases
published in clinical journals, most of the critical re-
marks have appeared in the health economics journals
and statistical literature. Therefore, we believe that intro-
ducing these issues to an audience of clinicians might
allow them to better appreciate the implications of ap-
propriate modelling of cost data on results and final
decision-making.
The present study describes the impact of analyzing
health care costs on results and conclusions in a popula-
tion affected by diabetes using different statistical
methods. Our data are affected by skewness and relevant
presence of zero cost observations, so the focus of our
paper will be on these two criticisms and how to manage
them using different statistical models.
Methods
Data
Diabetes patients were identified through the Piedmont
Diabetes Registry among the residents in the North-
Western Italian city of Turin (population: 896,914). The
Registry is based upon anonymous record linkage be-
tween administrative databases, lists of exemptions from
payment of drugs, hospital discharge records and pre-
scription databases. Details on the identification of the
population-based cohort are described elsewhere [14, 15].
Italian citizens, irrespective of social class or income, are
cared for by general practitioners and health care services
are supplied by the National Health System (NHS). All
drug prescriptions, outpatient treatment, diabetes related
prescriptions of medical devices, such as test strips, syrin-
ges, and glucometers, hospital discharges and emergency
room admissions are recorded by the Regional NHS
Administrative Databases. Data registered from August
1st, 2003 to July 31st, 2004 were linked to the overall
Turin population, making it possible to analyze health
care services used by patients with and without diabetes
(respectively n = 33,792 and n = 863,122). As previously
described, we analyzed reimbursement tariffs set by
regional and national government contracts [14]. In the
present study, data were used for tutorial purpose only
and for their distributive characteristics. An update of the
data was not included in the study aims.
The Piedmont Diabetes Registry is authorized to use
administrative health care data for epidemiological pur-
poses. Raw anonymous data are available upon request
to the Authors.
Cost analyses
Effect of diabetes on mean annual NHS expenditure was
analyzed over the entire cohort with several multivari-
able models, adjusted for age and gender.
First, we fitted one part models (Table 1), including: 1)
an ordinary least squares regression (OLS); 2) a lognor-
mal linear regression model; and 3) a generalized linear
model (GLM) with gamma distribution.
The OLS model relies on the central limit theorem
whereby the mean of a sufficiently large sample will be
approximately normally distributed, independently of
the population distribution. It assumes a linear relation-
ship between the cost accumulation and its possible de-
terminants (such as sex, age, type of diabetes etc.), with
an additive effect of the covariates – that is the cost is a
function of the Variable 1 effect plus the Variable 2 effect
plus the Variable 3 effect, etc., − and a normal distribu-
tion of the error term. As OLS regression is well known
and easy to apply, it is attractive for researchers and
widely employed. However, in presence of skewness in
the distribution of the error terms, OLS is not robust
enough and can estimate inaccurate standard errors and
confidence intervals. To overcome the problem of skew-
ness in the residuals, a commonly adopted approach is
to model a log-transformation of the response variable
(that is, costs) able to gain a reasonable normalization
effect even in presence of highly skewed data. To obtain
results in natural units (euros, dollars), the approach of
transforming the costs in any case requires a back-
transformation at the moment of interpreting results.
Such back-transformation might cause several additional
problems, partially avoided by using specific statistical
approaches (like the “smearing” estimator) [16]. In this
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Table 1 Determinants of annual healthcare costs, mean annual predictions and cost ratios (patients with vs. without diabetes), Root Mean Squared Errors (RMSE), by several data
modeling approaches
Model Diabetes (CI 95 %) Cost (€) per person/year,
patients with diabetes
(N = 33,792)
CI 95 %a Cost (€) per person/year,
patients without diabetes
(N = 863,122)
CI 95 %a Cost Ratio (with vs.
without diabetes)
RMSE
One-part models
Normal (€) 1,832.76 1,795.56–1,869.95 3348.6 3343.8–3353.9 831.2 829.8–832.4 4.03 3,342.4
Lognormalb (exp β) 6.0 5.84–6.16 6146.5 6116.9–6178.6 1343.6 1340.5–1347.0 4.57 3,670.0
Gamma (exp β) 2.6 2.56–2.67 3878.1 3867.0–3891.1 826.1 824.8–827.3 4.69 3,351.1
Two-part models
Part 1
Logistic (OR) 2.40 2.18–2.64 -
Part 2
Normal (€) 1,710.36 1,668.40–1,752.32 3392.0 3387.2–3397.5 1058.8 1057.4–1060.4 3.20 3,732.2
Lognormal (exp β) 3.3 3.21–3.32 4119.9 4104.4–4136.3 1175.2 1173.2–1177.6 5.60 3,760.6
Gamma (exp β) 2.2 2.21–2.28 3700.1 3690.0–3711.1 1050.8 1049.5–1052.4 3.50 3,735.6
Two part model (logistic + gamma) 3662.26 3652.07–3673.25 891.9 890.63–893.54 4.10 3,739.8
aderived by boostrapping method
bthe log transformed outcome variable was (cost + 1)
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analysis we applied the Duan smearing estimate [17],
that is the average of the exponential of the residuals
from the OLS regression on the log-transformed costs.
If ci(i = 1,…, n) is the cost observed for each patient, and
xj are the j(j = 1,…, h) covariates and βj are the j corre-
sponding regression coefficients estimated with the OLS
method, the smearing factor (Φ is:
Φ ¼ 1
n
Xn
i¼1
exp log cið Þ−xi β
∧
 
The exponentials of the predicted values were then
multiplied by the smearing factor to obtain expected
values on the original scale.
Moreover, in the present analysis the log transformed
outcome variable was (cost + 1), as we needed to include
all those subjects who had zero costs in the model also:
in fact they could not be simply treated as missing cases,
as they might convey relevant information on costs dis-
tribution among subgroups. It is common practice to
add a constant to null values, when fitting log-linear re-
gression models, in order to not exclude subjects from
the analysis [12]. This is an arbitrary choice, that could
bias the relationship between cost and covariates. How-
ever, sensitivity analysis shows that the distributions of
original and transformed cost, stratified by the covariates
used in the models, are substantially overlapped (data
not shown).
The GLM models are a generalization of the linear
model which specifies the relationship between a
dependent variable and a set of predictor variables and
allows the response variable to have other than a normal
distribution [18, 19]. GLMs permit flexible modelling of
covariates and enable inference to be made directly
about the mean costs, rather than focusing on trans-
formation methods. The relationship between the covar-
iates and the mean of the dependent variable is
described by the link function. The family specifies the
distribution (such as normal, gamma, Poisson, etc.) that
reflects the mean-variance relationship. As in most pre-
vious costs analyses, we used a Gamma distribution with
a log link, that performs satisfactorily with distributions
with zeroes and/or long right tails [13]. Lognormal and
GLM are both multiplicative models, because they are
expressed in logarithmic scale. This means that, due to
the algebraic properties of logarithms, cost is a function
of the exponential of the multiplied variables, after re-
transformation in the original scale. Consequently, the
comparison of the estimated costs cannot be directly
interpreted, due to the scale of the model and the tech-
nique of retransformation used.
In the second group of analyses (two part models,
Table 1), the zero costs presence was handled by means
of a two part model [20]: i) in the first part, a logistic
regression was used to model the probability of incur-
ring any cost over the one year period. The dependent
variable was set equal to 1 in any subject who incurred
costs, and was set equal to 0 in any subject who incurred
in 0 costs. We also included covariates to adjust for age,
sex and presence of diabetes. Odds ratios (ORs) for
probabilities of using health services (i.e. of not provid-
ing zero cost) were then estimated; ii) the second part
estimated the total accumulated costs, conditional on in-
curring any cost, by using the same set of three models
applied in the one-part model group and described
above. In this two-part set of analyses, the lognormal lin-
ear regression has not required to add 1 to the observed
costs.
Cost ratios of patients with diabetes vs. those without
diabetes were then estimated. Finally, estimated costs for
patients with and without diabetes were calculated
multiplying the expected probability of spending for
health care by the estimated costs for people using
health care (results shown only for gamma model).
Due to the uncertainty on the parametric assumption
of the distributional forms, confidence intervals were
calculated using a bootstrapping simulation process
which is a data-based simulation method for assigning
measures of accuracy to statistical estimates, used to
produce inferences such as confidence intervals without
knowing the type of distribution from which a sample
has been taken. The bootstrap simulates what would
happen if repeated samples of the population could be
taken by constructing a number of resamples with re-
placement of the observed dataset. Standard errors of
the parameter of interest are then estimated by the
standard deviation of the parameter in the simulated
samples. We extracted bootstrapping samples using a
SAS System macro-generating 100 bootstrap random
samples of patients [21].
To assess the performance of each model, the root
mean square error (RMSE) was computed for each
model. RMSE is a frequently used measure of the differ-
ence between values predicted by a model and values ac-
tually observed, providing the models are expressed in
the same unit of measure, as in our case [20]. These in-
dividual differences are also called residuals, and the
RMSE serves to aggregate them into a single measure of
predictive power. Since the errors are squared before they
are averaged, the RMSE gives a relatively high weight to
large errors. A RMSE value closer to 0 is desirable.
All the analyses were conducted using the SAS System.
Results
On July 31, 2003, 33,792 of the 896,915 Turin residents
were classified as patients with diabetes. As previously
described [14], the mean age of patients with diabetes
was 67.7 years and 44.3 years for patients without
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diabetes. Twenty one percent of the cohort of patients
with diabetes were treated with diet, 52.8 % with oral
drugs and 26.2 % with insulin; 1,703 people (0.05 %)
where considered as type 1 diabetes, while 32,089 people
(99.5 %) as type 2 diabetes.
The overall cohort was characterized by the presence
of a relevant subgroup with zero annual costs (21.5 %
patients without diabetes and 1.3 % among patients with
diabetes). Observed mean costs per person/year were
€ 3,348.6 (median € 1,314.9) in patients with diabetes
and € 831.2 (median € 110.0) in patients without
diabetes.
Table 1 shows the results of the applied multivariate stat-
istical models, adjusted for age, gender and presence of dia-
betes. The first three rows refer to one part models. The
OLS provided the effect of covariates in terms of absolute
additive costs due to the presence of diabetes (€ 1,832).
Lognormal and GLM provided a relative estimate of the ef-
fect: a 6-fold cost increase for diabetes versus non diabetes
with the lognormal and a 2.6-fold increase with the GLM.
The ratio between the estimated costs for patients with
and without diabetes varies from 4.03 with the OLS to 4.69
with the GLM.
However, as shown in Fig. 1, the cost distribution was
asymmetric (skewness coefficient: 14.3) and non-normal
(Kolmogorov-Smirnov test: p < 0.01), due to the presence
of zero cost observations and a relatively small propor-
tion of people incurring extremely high costs. As a re-
sult, the assumption of normality in the distribution,
required by the OLS model, did not hold and the coeffi-
cients estimated using this model could have been
biased. The lognormal regression showed a greater prob-
ability of higher cost for patients with diabetes and
higher estimated mean costs per person/year. The
Gamma model provided final estimates close to the OLS
albeit in presence of a statistically significant difference
both in patients with and without diabetes, determining
a higher cost ratio between the two groups (4.69).
The following four rows of Table 1 refer to the two
part models. The first part of the model analyzed the
probability of having had any costs (case with 0 costs)
using a logistic regression. Results showed that the prob-
ability of incurring healthcare costs was higher for
patients with diabetes than for those without diabetes
(OR: 2,4; 95 % CI: 2.18–2.64). The pattern of estimated
coefficients was similar to that obtained through the one
part model, with the loglinear model showing higher
estimated cost. The cost ratios estimated from the sec-
ond part of the models referred to the treated patients
only. The different percentage of zero cost observations
in the two groups determines a relevant variation from
the ratios estimated previously in the one part models.
The last row of Table 1 shows the estimated costs and
cost ratio for the two-part gamma model, taking into
account the probability of spending and the effective
expenditure. The estimated cost ratio between patients
with and without diabetes, considering the presence of
zero cost observations in the two groups, was 4.10.
The RMSE was higher for loglinear model, whereas
similar values were found for the other two models.
Discussion
Our study provides a practical example of the relevance
of using appropriate methods of analyzing costs of a
chronic disease. Indeed, we showed that different
methods provided substantially different estimated costs
for patients with and without diabetes, and different
costs ratios between them, ranging from 3.2 to 5.6. The
Fig. 1 Distribution of annual healthcare costs among residents in the city of Turin (n = 896,915). Note. Excluded subjects with zero costs (20.8 %)
and costs above 1000 euros
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range or variation of such estimated effects is relevant
for health care planners; therefore careful choice of
methods to analyze data is required before inferring
results.
The increased availability of administrative date
sources has largely increased the number of studies
examining diseases-related costs, with the final aim of
monitoring health care expenditure, identifying hetero-
geneities of expenditure among subgroups of patients
and suggest strategies to improve resources. Moreover,
data obtained from cost of illness studies are increasingly
being incorporated into models used for assessing the
cost-effectiveness of disease intervention, which assign
incremental costs to specific subgroups of patients [22].
With respect to traditional epidemiologic research how-
ever, studies on costs of diseases are characterized by
different methodological issues, which need to be appro-
priately handled to avoid biased results and wrong infer-
ences about the distribution of patients’ health care
costs. Healthcare cost distributions are typically affected
by several criticisms, such as asymmetry, heteroscedasti-
city, presence of zero observations and censoring [13].
Although several methodological approaches have been
identified in specialized literature in order to face prop-
erly such drawbacks, they are generally poorly known by
clinicians. As an example, recent literature on diabetes
costs is increasingly adopting non-traditional modeling
methods [23–27]. However, the clinical audience is
rarely skilled enough to understand the relevance of
adopting appropriate methodological approaches.
Administrative data sources allows to manage large
datasets and, as a general rule, when sample sizes are
sufficiently large for the central limit theorem to exert it-
self, simple methods should be preferred. Nevertheless,
also in large datasets, such as the one analyzed in the
present study, the assumption of normality was not jus-
tified. Indeed, the cost distribution was strongly asym-
metric and characterized by the presence of a relevant
portion of subjects not using health services, particularly
among patients without diabetes.
When applying different modeling approaches to dis-
ease costs, results show certain variability in the coeffi-
cient estimation because of the nature of the model, the
units of measurement and the relative technique of re-
transformation. Moreover, the determination of the best
performing model was not straightforward.
In our illustrative analysis, the loglinear model over-
estimated the effects with a low model precision. OLS
regression holds on the assumption of normality,
which was not supported by the skewness of the costs
distribution of our data. Estimated costs were slightly
underestimated among patients with diabetes com-
pared with models that take into account the asym-
metry of the distribution. Finally, the one part model
ignored the information related to the zero costs
observations.
Consistently, with application in other field of analysis
[28–32], the evaluation of the best model for cost esti-
mation of diabetes is not immediate.
Cost distribution characteristics and the objectives of
the study should be fine-tuned to define the analysis
plan.
If the study is focused on the analysis of health care
system for policy planning, the two-part models should
be preferred, because it makes it possible to quantify the
global propensity to use healthcare resources, including
subjects at zero costs.
If the focus is the estimation of the effect on cost of
single covariates, − such as age, comorbidities, setting of
care- a proper modelling of the observed positive costs
is acceptable and easily interpretable.
Conclusion
This study shows that costs estimates of a chronic dis-
ease vary considerably depending on the statistical
method employed. Researchers involved in cost analyses
as well as the potential users of the study results (clini-
cians and health care planners) should be aware of the
impact of methodological choices on final results and
interpretation.
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